drugset / Trial / NCT01993329
A Study to Evaluate the Effect of Gefapixant (AF-219/MK-7264) on Methacholine Hyper-reactivity in Participants With Asthma (MK-7264-009)
Phase 2
Completed
20 enrolled
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
RandomizedCrossoverQuadruple-blindTreatment
Summary
This is a randomized, double-blind, double-dummy, placebo-controlled, three-way cross-over, single centre study in participants with asthma undergoing inhalation of methacholine and adenosine triphosphate (ATP) to assess the provocative concentration (PC20) response of two dose levels of gefapixant (AF-219) compared with placebo.
Timeline
- Start
- 2013-12-16
- Primary completion
- 2014-02-20
- Completion
- 2014-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefapixant | Small molecule | 50 mg | Oral |
| Subject | Gefapixant | Small molecule | 300 mg | Oral |